2021
- 404-1-110/19-84 – Notification of Concluded Contracts for Q1 2021 – Medications from List A and List A1 of Medications
- 404-1-110/20-2 – Notification of Concluded Contracts for Q1 2021 – Medications from the List of Medications for Insured Persons of the Fund
- 404-1-110/20-3 – Notification of Concluded Contracts for Q1 2021 – Original and Innovative Medications for Insured Persons of the Fund
- 404-1-110/20-16 – Notification of Concluded Contracts for Q1 2021 – Public Procurement of Medicines for the Treatment of Rare Diseases
- 404-1-110/20-20 – Notification of Concluded Contracts for Q1 2021 – Cytostatics from List B and List D of Medicines for Insured Persons of the Fund
- 404-1-110/20-41 – Notification of Concluded Contracts for Q1 2021 – Medicines from List C of Medicines
- 404-1-110/20-46 – Notification of Concluded Contracts for Q1 2021 – medications from list B and list D of the medications for insured persons of the fund
- 404-1-110/20-52 – Notification of Concluded Contracts for Q1 2021 – public procurement of medications for the treatment of rare diseases
- 404-1-110/20-53 – Notification of Concluded Contracts for Q1 2021 – public procurement of medications from list A and list A1 of the medications for insured persons of the fund
2020
- JN 404-1-110/19-28 Medications from List B and List D of the drug list for 2019 – Q1
- JN 404-1-110/19-40, MEDICATIONS FOR THE TREATMENT OF RARE DISEASES – Q1
- JN 404-1-110/20-3, ORIGINAL AND INNOVATIVE MEDICATIONS FOR INSURED PERSONS OF THE FUND, attached is the Notification of concluded contracts for Q2 2020.
- JN 404-1-110/20-2, MEDICATIONS FROM THE DRUG LIST FOR INSURED PERSONS OF THE FUND, attached is the Notification of concluded contracts for Q2 2020.
- JN 404-1-110/19-100, MEDICATION PHYTOMENADIONE (VITAMIN K1) 2MG AND 10MG FOR INSURED PERSONS OF THE FUND, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/19-98, MEDICATIONS FOR TREATING PERSONS NOT INSURED WITH RFZO, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/19-84, MEDICATIONS FROM LIST A AND A1 OF MEDICATIONS FOR 2020, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/19-41, MEDICATIONS FROM LIST C, LIST OF MEDICATIONS FOR 2019, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/19-28, MEDICATIONS FROM LIST B AND LIST D, LIST OF MEDICATIONS FOR 2019, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/19-15, CYTOSTATICS FROM LIST B AND LIST D, LIST OF MEDICATIONS FOR 2019, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/20-4, REAGENTS, EXEMPTIONS FOR TRANSFUSION, attached is the Notification of concluded contracts for Q1 2020.
- JN 404-1-110/19-15 – CYTOSTATICS FROM LIST B AND LIST D OF MEDICINES FOR 2019, attached is the Notification of concluded contracts for Q3 2020.
- JN 404-1-110/19-28 – MEDICINES FROM LIST B AND LIST D OF MEDICINES FOR 2019, attached is the Notification of concluded contracts for Q3 2020.
- JN 404-1-110/19-41 – MEDICATIONS FROM LIST C OF THE LIST OF MEDICATIONS FOR 2019, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/19-84 – MEDICATIONS FROM LIST A AND LIST A1 OF THE LIST OF MEDICATIONS FOR 2020, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/19-100 – MEDICATION PHYTOMENADIONE (VITAMIN K1) 2mg AND 10mg FOR INSURED PERSONS OF THE FUND, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/20-2 – MEDICATIONS FROM THE LIST OF MEDICATIONS FOR INSURED PERSONS OF THE FUND, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/20-3 – ORIGINAL AND INNOVATIVE MEDICATIONS FOR INSURED PERSONS OF THE FUND, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/20-16 – PUBLIC PROCUREMENT OF MEDICATIONS FOR THE TREATMENT OF RARE DISEASES, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/20-52 – PUBLIC PROCUREMENT OF MEDICINES FOR THE TREATMENT OF RARE DISEASES, attached is the Notification of Concluded Contracts for Q3 2020.
- JN 404-1-110/20-4, REAGENTS, EXCLUDING FOR TRANSFUSION, attached is the Notification of Concluded Contracts for Q2 2020.
- JN 404-1-110/20-4, REAGENTS, EXCLUDING FOR TRANSFUSION, attached is the Notification of Concluded Contracts for Q3 2020.